- $1.16m
- -$2.93m
- 12
- 51
- 13
- 15
Annual income statement for GRI Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.1 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3.15 | 4.89 | 9.26 | 6.93 | 11.4 |
Operating Profit | -3.15 | -4.79 | -9.26 | -6.93 | -11.4 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.46 | -4.82 | -9.3 | -7.02 | -13 |
Net Income After Taxes | -3.46 | -4.82 | -9.3 | -7.02 | -13 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.46 | -4.82 | -9.3 | -7.02 | -13 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.46 | -4.82 | -9.3 | -7.02 | -13 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,400 | -1,933 | -3,728 | -1,891 | -367 |
Dividends per Share |